Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
SAB Biotherapeutics
company
About
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
- 51 - 100
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $14M
- Industries
- Biotechnology,Clinical Trials,Therapeutics
- Founded date
- Jun 1, 2014
- Number Of Employee
- 51 - 100
- Operating Status
- Active
A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$15.42M
SAB Biotherapeutics has raised a total of
$15.42M
in funding over 2 rounds. Their latest funding was raised on
Jul 17, 2020 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 17, 2020 | Series B | $14M | 1 | — | — | Detail |
| Sep 7, 2016 | Grant | $1.42M | 1 |
National Institutes of Health
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
SAB Biotherapeutics is funded by 2 investors.
National Institutes of Health
and Merck
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Institutes of Health
|
Yes | Grant |
Merck
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
